Introduction
Poly(ADP-ribose) polymerase 1 (PARP1)-targeted therapeutics have had a major impact on pharmaceutical research and development, and just recently, a therapeutic PARP1 inhibitor, Lynparza (olaparib, Astra-Zeneca), was approved for clinical use by the FDA [1] [2] [3] . The therapeutic interest in PARP1 is rooted in the unique role of the enzyme in the DNA damage repair cascade. PARP1 inhibitors inflict their cytotoxic potential by inhibiting certain cellular responses to DNA damage events, leading to cell death [1, 4] . The potential therapeutic impact of PARP1 as a clinical target is high, but the enzyme has also attracted attention as a target for imaging agents. This observation is based on the finding that PARP1 is highly overexpressed in various forms of cancer [5] [6] [7] [8] [9] [10] [11] , and the degree of upregulation is linked to overall survival [7] . This implies that PARP1 is not only a Brandon Carney and Giuseppe Carlucci contributed equally to this work. Electronic supplementary material The online version of this article (doi:10.1007/s11307-015-0904-y) contains supplementary material, which is available to authorized users.
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Based on this data, we tested a fluorescent imaging agent, PARPi-FL [12, 13] , for imaging of PARP1 expression in vivo. In mouse models of glioblastoma, we showed that PARPi-FL is metabolically stable, clears quickly from the circulation, and that its tumor uptake is closely correlated with PARP1 expression levels [14, 15] . Orthotopic brain tumors were successfully imaged in vivo due to (i) overexpression of PARP1 in glioblastoma, paired with (ii) low expression in healthy brain tissue; (iii) high cell permeability of the imaging agent; and (iv) strong retention in PARP1-expressing nuclei, along with rapid clearance from off-target tissues/cellular compartments.
While the fluorescent PARPi-FL will be of use as a preclinical imaging tool for quantifying PARP1 and might be used as an intraoperative probe, we became interested in creating a positron emission tomography (PET) active companion imaging agent for PARPi-FL. A radiolabeled PARP1 tracer might represent a robust platform for non-invasive PARP1 imaging and could ultimately provide insight into the biology of tumors before and after administration of treatment.
Inspired by our earlier designs [13] [14] [15] [16] [17] [18] [19] and the work of others [20] 
Results

Chemistry and Radiochemistry
The molecular structure of [ 18 F]PARPi is based on the previously tested and validated (2H)-phthalazin-1-one scaffold of the small molecule therapeutic olaparib [21] . Our tracer was obtained by conjugating a 4-[
18 F]fluorobenzoic acid group to the PARP1 targeting small molecule. Its cold reference compound, [ 19 F]PARPi, was synthesized in a single synthetic step from 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one [21] and 4-fluorobenzoic acid, similar to coupling procedures applied earlier [13] (Fig. 1a) . [ 19 F]PARPi was obtained with an isolated yield of 43 %, and its identity confirmed by ESI-MS, ESI-HRMS, and NMR spectroscopy (Fig. S1a-S1b) .
The 
F]PARPi
First, we determined the ability of our tracer to bind to PARP1 in a biochemical assay, analogous to methods we have previously described [22] . We found that the IC 50 of [ 19 F]PARPi was 2.8±1.1 nM (Fig. S1c) , which is on par with the small molecule parent compound olaparib (5 nM, [21] 
In vitro Characterization of [ 19 F]PARPi
We determined on a subcellular level whether [ 18 F]PARPi binds to the same target as its parent compound olaparib. To show this, we performed in vitro assays with the nonradioactive [
19 F]PARPi, olaparib, and the fluorescent imaging agent PARPi-FL, which we have shown to be highly selective for PARP1 and suitable as a surrogate marker to infer the subcellular distribution of olaparib [18] . Labeling cells with PARPi-FL leads to strong nuclear fluorescence due to retention of the imaging agent by PARP1. In the presence of olaparib, the binding sites for PARPi-FL were occupied, and the observed fluorescence is reduced by 69.6 ±22.3 % and 71.2±20.0 % for U251 MG and U373 MG cells, respectively. Similarly, [ 19 F]PARPi was able to compete for the same binding sites as PARPi-FL, resulting in a reduction of fluorescence intensity in the nucleus by 80.0±10.8 % and 78.8±10.4 % for U251 MG and U373 MG cells, respectively (Fig. 2) .
Blood Stability and Blood Half-Life of [
F]PARPi
We estimated the in vivo stability of [ 18 F]PARPi by incubating the radiotracer in whole blood for up to 4 h. Over the given time period, no radioactive metabolites were observed, indicating excellent stability and potentially low bone uptake of the tracer for in vivo applications (Fig. S3) . The blood half-life of [ 18 F]PARPi was determined in athymic nude mice, which received the tracer via tail vein injection. Analogous to other small molecules of this type [13, 14, 18] , the agent was cleared rather quickly, with an alpha blood half-life of 1.27 min (85.51 %) and beta blood half-life of 31.14 min (14.49 %), resulting in a weighted blood half-life of t 1/2 (weighted)=5.6 min (Fig. 3a) .
Biodistribution
Biodistribution studies were performed in mice bearing subcutaneously injected U251 MG xenografts (n=12, Fig. 3b, c and Table S1 ). Tumor uptake at 2 h postinjection was 1.82±0.21 %ID/g for mice receiving the tumor-to-brain ratio was 54.9±14.1 (Fig. 3b) . A high uptake was also observed in the hepatobiliary system with liver uptake values of 3.98±0.56 and 3.61±2.04 %ID/g, small intestine uptake of 2.94±0.91 and 2.35±0.70 %ID/g, and large intestine uptake of 2.24±0.59 and 1.73±0.80 %ID/g for unblocked and blocked cohorts, respectively. We also found that lymph node and spleen uptake were high, with 2.80±0.51 and 4.04 ±1.23 %ID/g, respectively, and that their uptake was reduced after pre-injection of olaparib by 95 and 94 %, respectively (Fig. 3c) . Highly selective uptake in these organs is based on their rather high PARP1 expression, shown in immunohistochemical stainings, which were obtained in non-tumor-bearing mice (Figs. S4-S5 ). Our biodistribution data was corroborated by PET/X-ray computed tomography (CT) imaging, with whole axial and coronal slices of subcutaneous tumor-bearing mice receiving only [ 
Ex vivo Autoradiography
We used an orthotopic mouse model of U251 MG to determine the potential clinical impact of [ 18 F]PARPi as a non-invasive PARP1 imaging tracer. U251 MG cells expressed PARP1 at much higher levels than healthy brain, and orthotopic brain tumors had a high gradient in PARP1 expression (Fig. S7) . In order to assess the alignment of [ 18 F]PARPi retention and PARP1 expression on a microscopic level in vivo, tumor-bearing mice were injected with [ 18 F]PARPi and autoradiography was performed (Fig. 4a) . Using histology to localize the tumor regions of the brain, the autoradiographic analysis revealed significantly higher retention of [ 18 F]PARPi inside orthotopic tumor tissue than in healthy surrounding brain (Fig. 4b, 46 .66±14.94 AU and 0.06±0.02 AU for orthotopic tumor and surrounding brain, respectively). Similarly-and consistent with in vitro imaging-we found that pre-injection of olaparib and hence saturation of PARP1 binding sites lead to almost quantitative reduction of [ 18 F]PARPi (99 %, 0.44±0.41 AU and 0.03 ±0.01 AU for orthotopic tumor and surrounding brain, respectively). The uptake of [ 18 F]PARPi in orthotopic tumor tissue was distinctly higher than in muscle (Fig. 4b, c, 1 .36 ±0.21 AU and 1.50±0.31 AU for muscle tissue in tumorbearing and healthy mice, respectively).
PET/CT and PET/MRI Imaging in Orthotopic Mouse Models
We used both small-animal PET/CT and PET/magnetic resonance imaging (MRI) scanners to determine the accuracy and selectivity of non-invasive glioblastoma delineation with [ (Fig. 6 ).
Discussion
The goal of this study was to establish an imaging tracer that can non-invasively detect PARP1 expression of malignant tumors. We showed that [ 18 F]PARPi, a PARP1-targeted small molecule, specifically binds to the DNA-repair enzyme PARP1 both in vitro and in vivo. Moreover, we tested the targeted accumulation of [ 18 F]PARPi in orthotopic mouse models of glioblastoma and have shown with autoradiography PET/CT and PET/MRI that the tracer was retained inside of glioblastoma tissue, but not the surrounding healthy brain. This reflects the overexpression of PARP1 in orthotopic glioblastoma models (Fig. S7) , which is consistent with our earlier findings [14, 15] and analogous to the human situation [9] .
For the synthesis of [ 18 F]PARPi, we replaced the cyclopropane group from the PARP1-targeted (2H)- 18 F]PARPi (n=12) calculated from biodistribution data. c Biodistribution study in selected tissues. After injection of [ 18 F]PARPi into mice with tumor xenografts, mice were euthanized at 2 h post-injection and radioactivity in organs was measured (n=6/group). Error bars are mean±SD. P values were calculated with Student's t-tests, unpaired; *PG0.05; **PG0.01; ***PG0.001; ****PG0.0001.
phthalazin-1-one scaffold and with a 4-[
18 F]fluorobenzene to yield the target molecule, a strong binder of PARP1 (2.8 ±1.1 nM). The radiochemical synthesis was straightforward, highly reproducible (Fig. S2) , and produced the tracer in excellent yield (10 %, overall uncorrected radiochemical yield), radiochemical/chemical purity (999 %), and specific activity (48 mCi/μmol). Similar to what was already described by other groups [24, 25] , the first two steps produced 4-[
18 F]fluorobenzoic acid in high yield. These steps were followed by efficient conjugation to the phthalazinone precursor in the presence of HBTU.
[
18 F]PARPi was rapidly washed out from most organs, resulting in a remarkable tumor-to-normal tissue contrast (Fig. 5 ) at 2 h post-injection for subcutaneous and orthotopic tumors. The tumor uptake of [ 18 F]PARPi at 2 h was 2.2 ±0.8 %ID/g and 1.82±0.21 %ID/g for orthotopic and subcutaneous U251 MG xenografts, respectively, and higher than that of other PARP1 targeting molecules of this type [14, 19] . Moreover, 2 h post-injection, low activity concentrations were observed in most organs except for the gastrointestinal tract due to the rapid clearance from the blood and subsequent hepatobiliary excretion of the tracer (liver, 3.98±0.56 %ID/g; small intestines, 2.94±0.91 %ID/g; large intestines, 2.24±0.59 %ID/g). This is analogous to olaparib [26] and other PARP1-targeted molecules [14, 15, 27] .
For PET/CT imaging in orthotopic U251 MG glioblastoma-bearing mice, imaging at 2 h rather than at 30 min post-injection yielded significantly higher tumor contrast by allowing the tracer to clear from the bloodstream and unspecific binding sites (Fig. 5 and Fig. S6 , Table S1 ). PET quantification showed an uptake in the tumor of 2.88 ±0.65 %ID/g at 0.5 h post-injection and 2.15±0.28 %ID/g at 2 h post-injection.
Expanding on our in vivo imaging data, we confirmed the co-localization of [ 18 F]PARPi and tumor in PET/MRI studies and ex vivo autoradiography. In PET/MRI fusion images, accumulation in the tumor was co-aligned with the orthotopic tumor on MRI (Fig. 6, ∼2 %ID/g ). In mice receiving an injection of olaparib ahead of the radiotracer, the [
18 F]PARPi tumor uptake was negligible (Figs. 5 and 6 ). This was also confirmed by ex vivo autoradiography (Fig. 4) , in which a stark difference between tumor and non-targeted tissues (brain and muscle) was seen, which is likely the result of fast penetration and rapid washout kinetics of this class of imaging agents [18] .
[ 18 F]PARPi combines good pharmacokinetic properties with remarkable in vitro and in vivo stability, evidenced by minimal defluorination. As result of the high lipophilicity of [ 18 F]PARPi, clearance mainly occurred via the hepatobiliary pathway, similar to olaparib and other PARP1-targeting molecules [14, 15, 27] . While imaging of glioblastoma with [ 18 F]PARPi in orthotopic mouse models was successful, it is a limitation of this model that the breakdown of the blood brain barrier can contribute to higher unspecific binding. Some of the tracer might have leaked out non-specifically into the tumor tissue due to this effect, contributing to the overall imaging signal. However, [ 18 F]PARPi uptake can be reduced significantly after injection of olaparib (PG0.0001), which suggests that at least in areas where the blood brain barrier is disrupted, specific binding is observed. Retention of [ 18 F]PARPi in the lymph nodes and spleen was also blocked by injection of olaparib, and the uptake therefore likely reflects PARP1 expression in immune cells, which has been described in the literature [5] and is consistent with our histological findings (Figs. S4, S5 ).
Conclusion
The novel PET imaging agent [ 18 F]PARPi demonstrates an outstanding ability to non-invasively image PARP1 expression of gliomas and could have various applications in brain tumor research. Besides serving as a companion imaging agent for PARP1-targeting therapeutics, the agent could serve as a diagnostic for monitoring PARP1 expression before, during, and after treatment with cytotoxic agents. This could lead to new insights into the function of PARP1 during cellular DNA damage response. Furthermore, the biodistribution data indicates that the imaging of PARP1 expression is not only feasible for brain tumors but potentially also for lung and soft tissue tumors. This is of high clinical relevance, because PARP1 inhibitors are under clinical investigation in lung cancer, breast cancer, and sarcomas. These properties make [ 18 F]PARPi an excellent candidate for clinical translation.
